Joseph R. Arron, MD PhD CSO and Head of Research & Development Sonoma Biotherapeutics Joseph Arron joined Sonoma Biotherapeutics as Chief Scientific Officer in 2023, after serving as a member of Sonoma’s Scientific Advisory Board. As head of R&D, he oversees clinical development activities for Sonoma's lead engineered regulatory T cell therapy program in multiple indications and preclinical research activities for 5 additional programs. Previously, Dr. Arron served as CSO at 23andMe Therapeutics from 2021-2023, leading target discovery, translational research, and preclinical drug development for diseases associated with human genetic variation across multiple therapeutic areas. Prior to joining 23andMe, Dr. Arron worked at Genentech from 2006-2021, where his laboratory discovered pathogenic mechanisms and molecular bases for heterogeneity in respiratory disorders, enabling target and biomarker discovery for numerous investigational molecular therapies and over 75 publications. As VP of Immunology Research, he led a department of >20 laboratories responsible for target and biomarker discovery, translational research, and preclinical therapeutic development in inflammatory, autoimmune, fibrotic, and ophthalmic diseases. Dr. Arron earned an undergraduate degree from Princeton University, completed a combined MD-PhD degree at Cornell University Medical College and the Rockefeller University, and conducted postdoctoral studies at Stanford University School of Medicine.